Thailand and the compulsory licensing of efavirenz.
Steinbrook
Robert
R
rsteinbrook@attglobal.net
D000480:Alkynes; D048588:Benzoxazines; D001938:Brazil; D003521:Cyclopropanes; D003906:Developing Countries; D016527:Drug Costs / Q000706:statistics & numerical data; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D018954:Drugs, Essential / Q000191:economics; D016568:Drugs, Generic; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007880:Legislation, Drug; D008004:Licensure / Q000331:legislation & jurisprudence*; D010078:Oxazines / Q000191:economics / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D013785:Thailand
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018954:Drugs, Essential; D016568:Drugs, Generic; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz